Redeye adjusts its financial and fair value estimates following Scandion’s conference call on CORIST part 2 top-line data. We judge CORIST part 2 will likely miss its primary efficacy endpoint, and modestly lower our estimated LoA and peak sales estimate for SCO-101. We adjust our fair value estimate accordingly.